v3.26.1
ACQUISITIONS (Tables)
 6 Months Ended
Jun. 30, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Summary of Business Combination
Total consideration transferred for the acquisition of Amicus is summarized as follows:

Cash paid to Amicus' shareholders$4,563,463 
Cash settlement towards Amicus’ RSUs and PSUs142,636 
Cash settlement towards pre-combination portion of stock options (1)
62,946 
Transaction expenses settled by the Company on behalf of Amicus121,596 
Amicus debt repayment by the Company on behalf of Amicus (2)
432,920 
Total consideration$5,323,561 
(1)Cash settlement towards the stock options consists of $51.9 million paid for vested stock options and $11.0 million paid for the pre-combination portion of unvested stock options that were accelerated as part of the acquisition. The fair value of the unvested stock options attributable to the post-combination period of $13.0 million is included in SG&A on the Company’s condensed consolidated statements of comprehensive income during the three and six months ended June 30, 2026
(2)Includes cash settlement related to repayment of outstanding debt, prepayment penalty and accrued interest.
The following table presents revenues and net earnings for Amicus since the acquisition date of April 27, 2026 through June 30, 2026:
Amount
Total revenue$136,006 
Net loss$(91,932)
Schedule of Recognized Asset Acquired and Liability Assumed
The following table summarizes the preliminary purchase price allocation of the assets acquired and liabilities assumed as of April 27, 2026:

Cash and cash equivalents$255,931 
Accounts receivable (1)
123,912 
Inventory469,700 
Other current assets55,052 
Property, plant and equipment25,923 
Intangible assets4,750,000 
Goodwill459,164 
Other assets59,219 
Accounts payable and accrued liabilities(205,466)
Deferred tax liabilities(565,050)
Other long-term liabilities(104,824)
Total assets and liabilities$5,323,561 
(1)    The Company expects to collect all contractual accounts receivable based on information available as of the acquisition date.
Schedule of the Purchased Intangible Assets Acquired
The following table presents details of the purchased intangible assets acquired:
Estimated Useful Life (in Years)Fair Value
Commercialized pharmaceutical product – GALAFOLD11$3,000,000 
Commercialized pharmaceutical product – POMBILITI + OPFOLDA121,450,000 
IPR&D - BMN 820Indefinite300,000 
Total intangible assets$4,750,000 
Schedule of Unaudited Pro forma Results of Operations
The unaudited pro forma results of operations for BioMarin as if the acquisition had occurred on January 1, 2025 are presented in the table below:
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Total revenue$1,038,914 $980,098 $1,984,908 $1,850,492 
Net income (loss)$(208,458)$97,347 $(200,907)$78,599